CN117264908A - 一种中国hsv临床分离株及基于其的溶瘤病毒和应用 - Google Patents
一种中国hsv临床分离株及基于其的溶瘤病毒和应用 Download PDFInfo
- Publication number
- CN117264908A CN117264908A CN202210660127.0A CN202210660127A CN117264908A CN 117264908 A CN117264908 A CN 117264908A CN 202210660127 A CN202210660127 A CN 202210660127A CN 117264908 A CN117264908 A CN 117264908A
- Authority
- CN
- China
- Prior art keywords
- gene
- virus
- recombinant
- tumor
- hsv1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000309459 oncolytic virus Species 0.000 title claims abstract description 101
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 77
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 73
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 28
- 241000700584 Simplexvirus Species 0.000 claims abstract description 17
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 241000700605 Viruses Species 0.000 claims description 78
- 210000004027 cell Anatomy 0.000 claims description 56
- 230000014509 gene expression Effects 0.000 claims description 54
- 239000013598 vector Substances 0.000 claims description 43
- 239000005090 green fluorescent protein Substances 0.000 claims description 29
- 230000008685 targeting Effects 0.000 claims description 29
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 26
- 108020004414 DNA Proteins 0.000 claims description 24
- 238000010276 construction Methods 0.000 claims description 22
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 20
- 239000013603 viral vector Substances 0.000 claims description 20
- 230000000174 oncolytic effect Effects 0.000 claims description 17
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 16
- 238000010367 cloning Methods 0.000 claims description 15
- 208000005017 glioblastoma Diseases 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 14
- 238000011144 upstream manufacturing Methods 0.000 claims description 14
- 210000003501 vero cell Anatomy 0.000 claims description 14
- 101150096316 5 gene Proteins 0.000 claims description 13
- 239000013600 plasmid vector Substances 0.000 claims description 12
- 230000003612 virological effect Effects 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 108010048367 enhanced green fluorescent protein Proteins 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 210000005036 nerve Anatomy 0.000 claims description 7
- 230000007923 virulence factor Effects 0.000 claims description 7
- 239000000304 virulence factor Substances 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 claims description 6
- 108010054624 red fluorescent protein Proteins 0.000 claims description 6
- 230000000120 cytopathologic effect Effects 0.000 claims description 5
- 102000034287 fluorescent proteins Human genes 0.000 claims description 5
- 108091006047 fluorescent proteins Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 238000001476 gene delivery Methods 0.000 claims description 4
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 238000007877 drug screening Methods 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 210000000653 nervous system Anatomy 0.000 claims description 3
- 238000011160 research Methods 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 2
- 230000003832 immune regulation Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 108700026220 vif Genes Proteins 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000010076 replication Effects 0.000 abstract description 14
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract description 10
- 238000012216 screening Methods 0.000 abstract description 9
- 238000012239 gene modification Methods 0.000 abstract description 4
- 230000005017 genetic modification Effects 0.000 abstract description 4
- 235000013617 genetically modified food Nutrition 0.000 abstract description 4
- 231100000053 low toxicity Toxicity 0.000 abstract description 4
- 206010027476 Metastases Diseases 0.000 abstract description 3
- 210000004881 tumor cell Anatomy 0.000 description 22
- 238000000746 purification Methods 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 206010018338 Glioma Diseases 0.000 description 7
- 230000002147 killing effect Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 208000032612 Glial tumor Diseases 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000037952 HSV-1 infection Diseases 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 208000030224 brain astrocytoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229940091204 imlygic Drugs 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000009447 viral pathogenesis Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种中国HSV临床分离株及基于其的溶瘤病毒和应用。本发明公开了一种单纯疱疹病毒临床分离株HSV1‑CH003株,其保藏编号为CCTCCNO:V202210。该单纯疱疹病毒HSV1‑CH003分离自中国流行的HSV1临床株,通过筛选以其作为溶瘤病毒骨架,经改造和优化所构建的HSV溶瘤病毒更适宜中国肿瘤患者。以HSV1‑CH003作为溶瘤病毒亲本株,经减毒、肿瘤靶向复制、武装化治疗基因等系列遗传改造,构建获得基于HSV1‑CH003临床株的重组溶瘤病毒,该溶瘤病毒毒性低,复制效率、安全性和有效性高,能够有效溶杀实体瘤和转移瘤。
Description
技术领域
本发明属于生物技术领域,涉及病毒学、分子生物学、神经生物学及肿瘤学、免疫学等,具体涉及一种中国HSV临床分离株及基于其的溶瘤病毒和应用,更具体地涉及一种中国HSV临床分离株、中国HSV临床分离株的应用、基于中国HSV临床分离株HSV1-CH003的溶瘤病毒及其构建方法和应用。
背景技术
近年来,肿瘤免疫疗法已逐渐成为继手术、化疗、放疗之后的第四大肿瘤治疗手段。溶瘤病毒作为一种新型肿瘤免疫生物疗法,为恶性肿瘤的治疗带来了新希望。溶瘤病毒(oncolytic virus,OV)是一类天然或者经过人工修饰改造,特异在肿瘤细胞内复制杀伤肿瘤而不伤及正常细胞的病毒。溶瘤病毒主要通过直接杀伤肿瘤细胞、诱导机体抗肿瘤系统性免疫以及阻止肿瘤血管生成等多方面实现治疗肿瘤目的,具有杀伤效率高、毒副作用小、适应症广以及成本低等优势。另外,当其与免疫检查点抑制剂、放/化疗等联合应用时,具有协同效应,可进一步提高肿瘤治疗的效果,有着巨大的应用前景,成为未来肿瘤治疗的新方向。
利用病毒治疗肿瘤的概念已有100多年的历史。随着基因工程技术的不断发展,溶瘤病毒已经发展到第三代,如今有160多种不同的溶瘤病毒正在进行临床前及临床试验。全球基于十余类病毒载体在研发溶瘤病毒药物,根据基因组构成,OV载体可分为两大类:一类是DNA病毒载体,其包括腺病毒、单纯疱疹病毒、痘病毒和细小病毒等;一类是RNA病毒载体,其包括呼肠孤病毒、脊髓灰质炎病毒、新城疫病毒、M1病毒和水泡型口炎病毒等。腺病毒和疱疹病毒是目前应用最多的两类溶瘤病毒载体。
2015年基于单纯疱疹病毒1型(Herpes simplex virus,HSV1)载体的溶瘤病毒药物Imlygic(Amgen公司产品,又名T-VEC)被美国FDA批准上市,作为黑色素瘤患者不可切除病灶的局部治疗方案。这是经过FDA批准的首个、也是唯一一个溶瘤病毒疗法,2016年在欧洲和加拿大也获批上市。2021年6月,日本第一三共株式会社的溶瘤HSV病毒产品G47Δ被日本厚生劳动省(MHLW)批准,用于治疗恶性胶质细胞瘤。两种oHSV溶瘤病毒的相继上市标志着溶瘤病毒技术的成熟,全球各大制药巨头纷纷通过收购或合作方式布局溶瘤病毒药物研发。
HSV-1在人群中广泛流行,主要引起口面部疱疹,国内高达90%的人在65岁时检测出血清HSV既往感染阳性。然而,HSV-1临床株(即从患唇疱疹个体中取样分离的病毒株)在进化生物学特性(如感染力、毒力、复制效率等)方面存在实质性的自然变异。目前全球基于单纯疱疹病毒开发的溶瘤病毒多是选用典型的HSV-1“实验室”标准株如17+、KOS或F株,这些毒株已通过长期的连续传代会被弱化,或可能不是溶瘤治疗的最佳病毒骨架。T-VEC最初是在将两个临床分离株与17+毒株进行比较后筛选的,两株临床株病毒对人肿瘤细胞的杀伤效果均优于17+毒株,其中最有希望的毒株JS1被筛选并构建转化为T-VEC。
目前溶瘤病毒行业尚存在技术瓶颈难题,如溶瘤病毒安全性、临床治疗实体瘤/转移瘤效果不佳、肿瘤靶向性弱、抗体中和作用、载体大规模制备效率低等。随着相关技术的快速发展,病毒载体层面的问题日益凸显,亟待攻关研制高效治疗实体瘤的新型溶瘤病毒,OV病毒载体的深度改造和优化仍是研发核心内容。基于国外HSV-1流行感染株和中国人群流行的HSV-1感染株势必不同、存在实质性的自然变异,所以筛选最适的病毒骨架来构建更适合国人和增效的新型HSV溶瘤病毒具有重要意义。
发明内容
为了解决溶瘤病毒开发现有技术中的不足,本发明旨在提供一种中国HSV临床分离株及基于其的溶瘤病毒和应用。
本发明提供一种单纯疱疹病毒HSV1-CH003株,其保藏编号为CCTCC NO:V202210。
本发明提供一种病毒载体,其通过首先敲除单纯疱疹病毒HSV1-CH003株基因组中神经毒力因子γ34.5双拷贝基因得到。
进一步地,所述病毒载体在敲除的γ34.5基因座位插入外源基因表达盒;或,
所述病毒载体还包括在其基因组任何插入不影响功能的位点插入外源基因表达盒;
所述外源基因表达盒中的外源基因选自表达任意目的蛋白的基因。
本发明提供所述的病毒载体在病毒学基础研究、作为大携载容量病毒载体、作为溶瘤病毒、作为目的基因递送载体、作为神经系统靶向基因治疗药物、在动物感染模型建立或抗病毒药物筛选中的应用。
本发明提供一种重组溶瘤病毒,其通过敲除单纯疱疹病毒HSV1-CH003株基因组中神经毒力因子γ34.5双拷贝基因得到靶向肿瘤细胞内复制的重组病毒。
进一步地,重组溶瘤病毒载体还包括在敲除的γ34.5基因座位插入肿瘤治疗序列基因表达盒,进一步增强溶瘤效果;或,
所述溶瘤病毒载体基因组还包括在任何插入不影响功能的位点插入肿瘤治疗序列基因表达盒,进一步增强溶瘤效果;
优选地,所述肿瘤治疗序列基因选自免疫检查点蛋白抗体基因、肿瘤免疫治疗细胞因子基因和免疫调控增强基因中的一种或以上;
优选地,所述肿瘤治疗序列基因表达盒包含启动子和肿瘤治疗序列基因;
优选地,在肿瘤治疗序列基因下游引入WPRE增强表达元件;
优选地,所述肿瘤治疗序列基因为免疫检查点蛋白PD1抗体基因;
优选地,在敲除的γ34.5基因座位还插入荧光蛋白表达盒,便于重组病毒筛选及在体感染标记指示,所述荧光蛋白表达盒的转录方向与所述肿瘤治疗序列基因表达盒保持一致。
本发明进一步提供上述重组溶瘤病毒在制备治疗抗肿瘤药物中的用途;
优选地,所述肿瘤包括脑瘤、恶性胶质母细胞瘤、宫颈癌、肺癌、胃肠癌、头颈癌、恶性间皮瘤、乳腺癌、恶性黑素瘤、血液肿瘤、多发性骨髓瘤、急性髓性白血病、慢性髓性白血病、非小细胞肺癌、结直肠癌、前列腺癌、卵巢癌、肝癌、肾癌、胰腺癌、胃癌、食道癌、胆管癌、头颈部鳞状细胞癌、软组织肉瘤和小细胞肺癌。
本发明提供一种抗肿瘤药物组合物,包含所述的重组溶瘤病毒。
本发明提供一种重组溶瘤病毒的构建方法,包括,敲除单纯疱疹病毒HSV1-CH003株基因组中神经毒力因子γ34.5双拷贝基因;
优选地,还包括在敲除的γ34.5基因座位或基因组任何插入不影响功能的位点插入肿瘤治疗序列基因表达盒。
本发明提供一种溶瘤病毒的构建方法,包括如下步骤:
(1)靶向载体构建
克隆γ34.5基因上下游同源臂,将克隆的上下游同源臂片段连入骨架载体,获得重组载体1;构建包括启动子(如hUbC、CMV启动子等)、绿色荧光蛋白基因和WPRE片段的EGFP表达盒(WPRE为土拨鼠肝炎病毒转录后调控元件,用于稳定和增强外源基因表达水平),连入重组载体1,获得表达绿色荧光蛋白的重组靶向质粒载体;
优选地,还包括在重组载体1插入肿瘤治疗序列基因表达盒,具体地:构建包括启动子(如hUbC、CMV等高效启动转录的启动子)、肿瘤治疗序列基因(PD1单链抗体基因)和红色荧光蛋白mCherry基因通过自剪切肽(2A)绑定表达的肿瘤治疗序列基因表达盒,替换表达绿色荧光蛋白的重组靶向质粒载体的EGFP表达盒,获得表达肿瘤治疗序列基因的重组靶向质粒载体。
(2)重组溶瘤病毒构建
将敲除γ34.5基因表达绿色荧光蛋白的重组靶向质粒载体与HSV1-CH003病毒株基因组DNA共转染293T细胞,待细胞病变后收集上清,感染Vero细胞,挑斑绿色荧光的病毒嗜斑,经过5轮以上的挑斑纯化后即得表达绿色荧光蛋白的重组病毒;
优选地,插入肿瘤治疗序列基因的重组溶瘤病毒的构建,方法包括:将表达肿瘤治疗序列基因的重组靶向质粒载体与表达绿色荧光蛋白的重组HSV CH003-Δγ34.5-hUbC-3EGFP-WPRE株病毒基因组DNA共转染293T细胞,待细胞病变后收集上清,感染Vero细胞,在绿色荧光背景下挑斑红色荧光的病毒斑,经过5轮以上的挑斑纯化后即得。
进一步地,本发明上述溶瘤病毒的构建方法,包括如下步骤:
(1)靶向载体构建
克隆临床株HSV1-CH003γ34.5基因上下游同源臂片段,设计引物克隆γ34.5基因上游同源臂(UHA,长440bp,GC含量78%)(SEQ ID NO.1),下游同源臂(DHA,长500bp,GC含量68%)(SEQ ID NO.2),将克隆的上下游同源臂片段以infusion技术连入基于pcDNA3.1+骨架构建的3.1+ΔRL1载体(实验室自主构建),克隆上下游同源臂片段选择的酶切位点分别为MluI和AgeI对,SbfI和XbaI对,在克隆的上下游同源臂中间引入一个多克隆位点接头,引入的6种内切酶分别是-AgeI-ClaI-EcoRI-EcoRV-KpnI-PacI-SbfI-,便于后续克隆外源基因或表达控制元件等插入靶向载体,获得的质粒载体命名为pHSV-CH003Δγ34.5。
以实验室自主构建的含hUbC-3EGFP表达框序列的质粒为模板,克隆三个绿色荧光基因串联的真核表达框片段hUbC-3EGFP(SEQ ID NO.3),以及WPRE-bGH PA片段(SEQ IDNO.4),hUbC是选用的启动活性强的泛素启动子,hUbC-3EGFP片段(长度3538bp)经ClaI、KpnI酶切连入pHSVCH003Δγ34.5载体获得pHSV-CH003Δγ34.5-hUbC-3EGFP载体;WPRE-bGH PA片段(长度846bp)经KpnI、PacI酶切连入pHSV-CH003Δγ34.5-hUbC-3EGFP载体,从而构建获得表达绿色荧光蛋白的重组靶向质粒pHSV-CH003Δγ34.5-hUbC-3EGFP-WPRE-bGH PA载体(SEQ ID NO.5)。
优选地,还包括插入肿瘤治疗序列基因表达盒,具体地:
合成肿瘤治疗序列基因序列,例如可以为表达PD1抗体(αPD1Ab)和粒细胞巨噬细胞集落刺激因子(GM-CSF)等。选择FUGW质粒(Addgene编号14883)作为重组靶向载体的构建骨架,此轮重组以hUbC启动子片段和WPRE片段作为同源臂,可替换掉上述靶向质粒载体中的3EGFP序列;合成PD1抗体的基因序列(αPD1)(SEQ ID NO.6),通过自剪切肽P2A和红色荧光蛋白(mCherry)基因(SEQ ID NO.7)串联获得表达框mCherry-P2A-αPD1Ab(SEQ IDNO.8);该表达框片段(长度1599bp)通过Infusion方法克隆入经BamHI、EcoRI双酶切的FUGW质粒,替换掉原来的EGFP荧光基因,获得重组质粒pFUW-hUbC-mCherry-P2A-αPD1Ab(SEQ IDNO.9)。
(2)重组溶瘤病毒构建
将pHSV-CH003Δγ34.5-hUbC-3EGFP-WPRE-bGH PA与HSV1-CH003病毒株基因组DNA共转染293T细胞,待大部分细胞表现出细胞病变后,收集细胞和上清,用离心后的细胞裂解液或上清感染Vero细胞,在细胞上覆盖含有2%胎牛血清、抗生素和1%琼脂糖的DMEM维持培养基,1天后观察感染细胞有无荧光表达确定新型病毒是否重组成功;2-3天后,挑斑分离良好的表达绿色荧光的病毒嗜斑,连续10倍稀释后感染新的Vero细胞进行下一轮挑斑纯化,经过5轮嗜斑挑斑、单克隆纯化,完全去除无荧光表达的野生型临床株HSV1-CH003病毒,获得纯化的溶瘤病毒HSV CH003-Δγ34.5-hUbC-3EGFP-WPRE;
优选地,插入肿瘤治疗序列基因的重组溶瘤病毒的构建,方法包括:
将重组质粒pFUW-hUbC-mCherry-P2A-αPD1Ab与所述溶瘤病毒HSV CH003-Δγ34.5-hUbC-3EGFP-WPRE基因组DNA共转染293T细胞,待大部分细胞出现细胞病变后,收集病毒上清,离心后取少量感染Vero细胞,去除上清液,并上铺含有2%胎牛血清、抗生素和1%琼脂糖的培养基,2-3天后挑斑分离良好的表达红色荧光的嗜斑,即绿色背景视野中挑取红色荧光的病毒斑,连续10倍稀释后感染新的Vero细胞进行下一轮纯化,经过5轮挑斑、单克隆纯化,完全去除表达绿色荧光蛋白的HSV1 CH003-Δγ34.5-hUbC-3EGFP母本病毒,获得单克隆化的携带肿瘤治疗序列基因序列的溶瘤病毒HSV CH003-Δγ34.5-hUbC-mCherry-P2A-肿瘤治疗序列基因序列-WPRE。
本发明的有益效果为:
(1)本发明提供的单纯疱疹病毒中国临床分离株HSV1-CH003是通过和临床医院合作从门诊唇疱疹患者采样分离获得,经筛选具备良好的病毒骨架性能,而非国外引进的传代次数不详的常见实验室标准株,以中国临床分离株HSV1-CH003作为溶瘤病毒骨架,经改造和优化所构建的HSV溶瘤病毒更适宜中国肿瘤患者人群治疗。
(2)本发明以HSV1-CH003作为OV亲本株,经减毒、肿瘤靶向复制、武装化治疗基因等系列遗传改造,构建获得基于HSV1-CH003的溶瘤病毒,经验证重组溶瘤病毒复制效率高,能够有效溶杀实体瘤和转移瘤。在HSV1-CH003溶瘤病毒基因组中插入表达PD1抗体(αPD1Ab)的基因,溶瘤病毒感染裂解肿瘤细胞的同时,病毒会直接表达免疫检查点蛋白抑制剂,达到溶瘤和免疫激活的协同杀瘤效应。体外和体内实验表明研制的oHSV-CH003溶瘤病毒具有良好的肿瘤细胞感染效率和溶瘤效果。
(3)本发明敲除HSV1-CH003病毒株最主要的神经毒力因子基因γ34.5后,可作为一种低毒、大容量的基于HSV临床株的外源基因长效高表达的基因递送病毒载体,可实现外源基因的高效转导及高丰度表达。
(4)本发明基于HSV1-CH003临床株改造的病毒载体适于做溶瘤病毒、外源基因长效高表达的基因递送载体等。另外低毒HSV1-CH003载体在神经系统靶向基因治疗、病毒复制与致病机理分析、动物感染模型建立、抗病毒药物筛选等方面具有广泛的应用价值。
附图说明
图1为HSV1-CH003-Δγ34.5-hUbC-3EGFP-WPRE基因组结构示意图;
图2为HSV1-CH003-Δγ34.5-hUbC-3EGFP-WPRE病毒重组、挑斑纯化的细胞图;
图3为构建的条件复制型HSV1-CH003重组病毒基因组分子鉴定;
图4为条件复制型HSV1-CH003-Δγ34.5-hUbC-3EGFP-WPRE溶瘤病毒骨架载体裂解肿瘤细胞效果分析;
图5为构建的溶瘤病毒oHSV CH003-Δγ34.5-hUbC-mCherry-P2A-αPD1Ab-WPRE(简写为oHSV CH003-Δγ34.5-αPD1Ab-mCherry)的基因组结构示意图;
图6为oHSV CH003-Δγ34.5-αPD1Ab-mCherry溶瘤病毒重组挑斑及纯化的细胞图;
图7为oHSV CH003-Δγ34.5-αPD1Ab-mCherry溶瘤病毒的在体毒性测试;
图8为U87MG-GFP恶性胶质瘤细胞株构建、纯化及外源荧光蛋白表达情况;
图9为构建U87MG-GFP恶性胶质瘤颅内荷瘤小鼠模型;
图10为oHSV CH003-Δγ34.5-αPD1Ab-mCherry溶瘤病毒能有效在体感染和溶杀恶性胶质瘤。
保藏说明
筛选出来的单纯疱疹病毒中国临床分离株HSV1-CH003,经单克隆纯化后的低传代株野生型病毒按要求和规定数量于2022年3月15日保藏于中国典型培养物保藏中心(ChinaCenter for Type Culture Collection,简称CCTCC),地址为中国.武汉.武汉大学。HSV1-CH003分类命名为单纯疱疹病毒中国临床分离株HSV1-CH003,保藏编号为CCTCC NO:V202210。
具体实施方式
为了更清楚地理解本发明,现参照下列实施例及附图进一步描述本发明。实施例仅用于解释而不以任何方式限制本发明。实施例中,各原始试剂材料均可商购获得,未注明具体条件的实验方法为所属领域熟知的常规方法和常规条件,或按照仪器制造商所建议的条件。
实施例1:单纯疱疹病毒临床株HSV1-CH003的分离、筛选
1、HSV临床株的分离与鉴定
通过与武汉大学人民医院、中国人民解放军中部战区总医院等临床医院皮肤科医生合作,从门诊口面部疱疹患者采样疱疹水疱液,经过培养、纯化、鉴定分离到26株HSV1型临床病毒株。通过克隆病毒gD、gB基因并测序,和从国外引进的F株、H129临床株比对基因序列均存在一定的碱基突变,而且分离的临床株间基因也存在差异,体现在进化生物学特性(如感染力、毒力、复制效率等)会存在差异,表明从中国健康人群分离的HSV临床株中比较和筛选溶瘤病毒亲本株很有必要。
2、HSV临床株的比较和筛选
从临床株筛选溶瘤病毒骨架载体的原则如下:①健康人群口面部疱疹来源;②基因型测序鉴定为HSV1型;③感染肿瘤细胞裂解活性高;④对阿昔洛韦敏感、无耐药性。通过系统比较临床毒株的复制效率、细胞毒性、裂解肿瘤细胞活性等,筛选出临床株CH003作为备选亲本株。单纯疱疹病毒临床株HSV1-CH003的保藏编号为CCTCC NO:V202210。
分离的HSV1临床株野生型病毒毒性还较大,经扩增纯化后颅内注射小鼠在3-5天内全部死亡。为研制溶瘤病毒药物,首先需要对HSV1临床株进行减毒和靶向复制改造等建立安全性的病毒载体。为开发更高效溶杀实体瘤的新型溶瘤病毒,设计集成采用中国临床病毒株、删除致病基因、免疫增强因子武装、携载免疫检查点蛋白抗体等多种增效策略,来研制高效溶杀实体瘤和转移瘤的增效oHSV。
实施例2:肿瘤靶向、条件复制型HSV1-CH003重组改造的靶向载体构建
(1)双拷贝神经毒力基因γ34.5敲除的靶向载体构建
敲除双拷贝γ34.5基因:克隆测序临床株HSV1-CH003γ34.5基因及其上下游序列,设计引物克隆γ34.5基因上游同源臂(UHA,长440bp,GC含量78%)(SEQ ID NO.1),下游同源臂(DHA,长500bp,GC含量68%)(SEQ ID NO.2);克隆的上下游同源臂片段以及荧光蛋白表达盒片段利用infusion技术连入基于pcDNA3.1+骨架构建的3.1+ΔRL1载体;克隆上下游同源臂片段时选择的酶切位点分别为MluI和AgeI对,SbfI和XbaI对,获得的质粒载体命名为pHSV-CH003Δγ34.5。该载体在克隆的上下游同源臂中间引入一个多克隆位点接头,引入的6种内切酶分别是-AgeI-ClaI-EcoRI-EcoRV-KpnI-PacI-SbfI-,便于后续克隆外源基因或表达控制元件等插入靶向载体。
具体步骤如下:
首先,分别使用以下引物扩增γ34.5UHA和DHA片段:
UHA-F:gtacgggccagatatacgcgtCGGGGCCGCGGGAGCGGGgggaggagc SEQ ID NO.12
UHA-R:TtaacccatcgatggaccggtGGAGACAGAGAGCGTGCCGgggtggtag SEQ ID NO.13
DHA-F:aatccttaattaaggcctgcaggCGTTACACCCGAGGCGGCctgggtcttc SEQ IDNO.14
DHA-R:ggtttaaacgggccctctagaCGGGCCAATGCGCGAGGGgccgtgtg SEQ ID NO.15
多片段重组使用的是来自南京诺唯赞公司的多片段infusion试剂盒。将获得的载体命名为pHSV-CH003Δγ34.5。
(2)携载绿色荧光蛋白基因表达盒的重组靶向载体构建
以实验室自主构建的含hUbC-3EGFP表达框序列的质粒为模板,克隆三个绿色荧光基因串联的真核表达框片段(hUbC-3EGFP)(SEQ ID NO.3),以及WPRE-bGH ploy(A)片段(SEQ ID NO.4),hUbC是选用的启动活性强的泛素启动子。hUbC-3EGFP片段(长度3538bp)经ClaI、KpnI酶切连入pHSV-CH003Δγ34.5载体获得pHSV-CH003Δγ34.5-hUbC-3EGFP载体;WPRE-bGH PA片段(长度846bp)经KpnI、PacI酶切连入pHSV-CH003Δγ34.5-hUbC-3EGFP载体,从而构建获得表达绿色荧光蛋白的重组靶向质粒pHSV-CH003Δγ34.5-hUbC-3EGFP-WPRE-bGH PA载体(SEQ ID NO.5)。
实施例3:肿瘤靶向、条件复制型HSV1-CH003溶瘤病毒重组、挑斑纯化
双拷贝神经毒力基因γ34.5完全敲除、携带表达EGFP的HSV1-CH003重组病毒构建:
为了获得病毒基因组中最主要神经毒力基因γ34.5双拷贝完全敲除的HSV1-CH003重组株,抽提靶向载体pHSV-CH003Δγ34.5-hUbC-3EGFP-WPRE-bGH PA与临床株病毒HSV1-CH003基因组DNA共转染培养在六孔板中的293T细胞,实验方法按照Lipofectamine2000(Invitrogen)说明书进行:待大部分细胞表现出细胞病变后,收集培养基,用PBS收集细胞。经三轮冷冻-震荡-涡旋后,用上清和细胞裂解液分别感染六孔板中的Vero细胞。感染1小时后,去除上清液,在细胞上覆盖含有2%胎牛血清、1%抗生素和1%琼脂糖的DMEM维持培养基。1天后观察感染细胞有无荧光表达确定新型病毒是否重组成功,2-3天后,挑斑分离良好的表达绿色荧光的病毒嗜斑,连续10倍稀释后感染新的Vero细胞进行下一轮挑斑纯化。经过6轮嗜斑挑斑、单克隆纯化,完全去除无荧光表达的野生型临床株HSV1-CH003病毒,获得纯化的重组病毒HSV1 CH003-Δγ34.5-hUbC-3EGFP-WPRE,病毒基因组示意图如图1,病毒重组挑斑及完全纯化的细胞图如图2所示,上排为重组病毒斑(绿色荧光)的荧光图和明场图;下排为重组病毒完全挑纯后的感染细胞荧光图及明场图。
实施例4:HSV1-CH003重组病毒的扩增制备
纯化后的HSV1-CH003重组病毒通过感染生长在10cm平皿上的Vero细胞进行批量生产及纯化。将重组病毒HSV1 CH003-Δγ34.5-hUbC-3EGFP-WPRE重组OV载体按照MOI=0.01感染Vero细胞,待细胞出现明显的变圆病变之后(大约3天),将含重组病毒的上清液收集到50mL离心管中,通过离心去除细胞碎片(6400rpm,10分钟),上清液使用0.22μm的滤膜过滤,最后使用贝克曼高速离心机进行浓缩(30000rpm,3小时);将浓缩后的重组病毒沉淀使用少量PBS(pH=7.4)重悬,在4℃条件下过夜,并不断摇动;第2天混匀病毒液,接着将重悬的重组病毒溶液加到20%的蔗糖溶液上层进行超速离心(30000rpm,3小时)、浓缩纯化;最后将溶解后的重组病毒进行分装,冻存在-80℃冰箱中。使用Vero细胞进行标准嗜斑实验来测定浓缩后HSV CH003重组病毒的滴度,滴度以每毫升的嗜斑形成单位(PFU/mL)表示。浓缩后的重组病毒HSV1 CH003-Δγ34.5-hUbC-3EGFP-WPRE滴度经测定约为5×109PFU/mL。
实施例5:条件复制型HSV1-CH003重组病毒基因组分子鉴定
取浓缩纯化的HSV1 CH003-Δγ34.5-hUbC-3EGFP-WPRE重组病毒(图3中简写CH003ΔRL1-U3G)、野生型wt CH003病毒作为阴性对照,在100℃灭活10分钟,后续用于hUbC-3EGFP基因片段的分子鉴定。以hUbC-3EGFP基因片段(3538bp)设计引物,引物序列为U3G-F:5'gcgccgggttttggcgcctcccgcggg 3'(SEQ ID NO.10);U3G-R:5'CTATAGGATATCGAATTCctTGTACAGC 3'(SEQ ID NO.11)。PCR反应体系为50μL,其中灭活病毒样用量为1-5μL,PCR buffer 10μL,20μM/μL引物各0.7μl,dNTPs 5μL,Prime star HS高保真酶0.6μL,补灭菌水到50μL。PCR扩增条件为:98℃5min,(98℃30s,60℃30s,72℃3min)循环32次,72℃延伸10min,16℃30min。分子鉴定结果如图3所示,阴性对照为野生型HSV1-CH003病毒,hUbC-3EGFP基因片段引物未扩出条带;阴性对照(H306)无条带;而构建的重组溶瘤病毒CH003Δγ34.5-U3G扩增出3.5Kb大小的目的条带,结果说明HSV1 CH003-Δγ34.5-hUbC-3EGFP-WPRE重组溶瘤病毒外源基因已成功插入并替换敲除了CH003病毒基因组的γ34.5基因。
实施例6:肿瘤靶向、条件复制型HSV1 CH003-Δγ34.5-hUbC-3EGFP-WPRE溶瘤病毒骨架溶瘤效果分析
HSV1-CH003临床株病毒通过遗传改造敲除最主要的神经毒力基因γ34.5,赋予了病毒在机体内只能靶向肿瘤细胞内复制扩增、裂杀肿瘤细胞的特性,而感染正常的机体细胞为复制缺陷型,不能增殖产生子代病毒。为检测构建的HSV1 CH003-Δγ34.5-hUbC-3EGFP-WPRE溶瘤病毒骨架的溶瘤效果,以HSV1 CH003重组病毒感染常见的肿瘤细胞株进行测试。
图4所示为体外培养的恶性胶质母细胞瘤细胞株U87MG以及溶瘤病毒感染裂解细胞的结果:没有感染病毒的U87MG恶性胶质瘤细胞胞体呈现聚团以及长而明显的细胞突起和胞间网络化形态;将制备的HSV1 CH003-Δγ34.5-hUbC-3EGFP-WPRE溶瘤病毒按MOI=0.01感染U87MG细胞,感染后12小时就能观察到肿瘤细胞感染重组病毒后表达绿色荧光蛋白,24小时观测大部分肿瘤细胞均被感染、胞体呈绿色荧光;第2天后肿瘤细胞出现明显的细胞病变,细胞突起萎缩变圆;到第3天U87MG细胞全部圆缩,大部分细胞已凋亡(图4),结果表明基于临床分离的HSV1-CH003临床株改造构建的重组溶瘤病毒HSV1CH003-Δγ34.5-hUbC-3EGFP-WPRE能高效的感染并裂杀恶性肿瘤细胞。
实施例7:武装化PD1抗体基因的HSV1-CH003溶瘤病毒构建
目前应用溶瘤病毒开展的临床治疗或临床试验中均发现OV联合免疫检查点抑制剂给药具有协同效应,溶瘤病毒能实现更好的溶瘤效果。本实施例设计通过遗传改造使HSV重组病毒基因组进一步直接携带抗PD-1蛋白的抗体基因,这样其感染裂解肿瘤细胞的同时可在肿瘤细胞内组成性表达PD-1蛋白抗体,从而达到联合用药的增效目的,且能降低成本、简化临床联合给药途径,溶瘤病毒复制增殖和免疫检查点抑制剂表达均在感染的肿瘤细胞内完成,能更好的靶向协同实现高效溶杀肿瘤目的。
选择FUGW质粒(Addgene编号14883)作为重组靶向载体的构建骨架;合成PD1抗体的基因序列(αPD1)(SEQ ID NO.6),通过自剪切肽P2A和红色荧光蛋白(mCherry)(SEQ IDNO.7)基因串联获得表达框mCherry-P2A-αPD1Ab(SEQ ID NO.8);该表达框片段(长度1599bp)通过Infusion方法克隆入经BamHI、EcoRI双酶切的FUGW质粒,替换掉原来的EGFP荧光基因,获得重组质粒pFUW-hUbC-mCherry-P2A-αPD1Ab(SEQ ID NO.9)。oHSV1-CH003基因组携载PD1抗体基因的重组病毒构建步骤如下:将抽提的靶向载体pFUW-hUbC-mCherry-P2A-αPD1Ab与上述构建的重组病毒HSV1CH003-Δγ34.5-hUbC-3EGFP-WPRE基因组DNA共转染293T细胞,质粒转染表达红色荧光蛋白,而病毒感染的细胞同时表达绿色荧光蛋白,如果重组成功mCherry-P2A-αPD1Ab基因序列会同源重组替换掉3EGFP基因,新重组病毒将只表达红色荧光蛋白;待大部分细胞出现细胞病变后,收集细胞和病毒上清。经三轮冷冻-震荡-涡旋后,感染六孔板的Vero细胞,1小时后去除上清液,并上铺含有2%胎牛血清、抗生素和1%琼脂糖的培养基。2-3天后挑斑分离良好的表达红色荧光的嗜斑,即绿色背景视野中挑取红色荧光斑,连续10倍稀释后感染新的Vero细胞进行下一轮纯化。经过5轮挑斑、单克隆纯化,完全去除表达绿色荧光蛋白的HSV1 CH003-Δγ34.5-hUbC-3EGFP-WPRE母本病毒,获得单克隆化的携带PD1抗体基因的溶瘤病毒oHSV1 CH003-Δγ34.5-hUbC-mCherry-P2A-αPD1Ab-WPRE(缩写为oHSVCH003-Δγ34.5-αPD1Ab-mCherry),病毒基因组示意图如图5,病毒重组挑斑及纯化的细胞图如图6所示。
实施例8:武装化PD1抗体基因的oHSVCH003-Δγ34.5-αPD1Ab-mCherry溶瘤病毒的在体毒性测试
将构建的溶瘤病毒oHSVCH003-Δγ34.5-αPD1Ab-mCherry(实验室编号:H526)大量扩增、纯化浓缩,经嗜斑实验测定制备的溶瘤病毒滴度为8×109PFU/mL。经颅内注射2×106PFU病毒感染小鼠VTA脑区,观察小鼠一直状态良好;14天后灌流小鼠、取脑组织切片观察,可见在注射脑区VTA和病毒经末梢吸收感染的脑区LH、LHb等都有很好的红色荧光标记,只在注射部位观察到有一定炎症反应,其它脑区标记到的神经元都状态良好(图7)。相对的HSV1-CH003野生型病毒感染小鼠症状明显、一周内小鼠全部死亡。实验表明本发明构建的oHSVCH003-Δγ34.5-αPD1Ab-mCherry溶瘤病毒具有低毒性、携载的外源抗体蛋白等得到高效表达,感染机体正常组织如神经元细胞溶瘤病毒为复制缺陷型,不会增殖传播致死动物。
实施例9:构建表达绿色荧光蛋白的人源恶性胶质母细胞瘤细胞株U87MG-GFP
为构建新型肿瘤荷瘤动物模型测试oHSVCH003溶瘤病毒效果,建立人源肿瘤细胞株工程化改造技术。利用慢病毒会整合到宿主细胞基因组的特性来构建组成性表达目的蛋白的新型U87MG稳转细胞株;为便于新细胞系的流式细胞筛选纯化,首先构建并制备表达绿色荧光蛋白的慢病毒LentiV-hUbC-EGFP-WPRE;人源胶质母细胞瘤细胞株U87MG感染慢病毒后能稳定表达绿色荧光蛋白,经流式分选纯化后获得新型恶性胶质瘤细胞株U87MG-GFP;如图8所示,制备的工程化细胞株U87MG-GFP纯度很高,几乎所有细胞都稳定表达绿色荧光蛋白,而且细胞状态良好,和野生型U87MG一致,保种到基于U87MG工程化改造的胶质瘤细胞库。
实施例10:利用遗传改造的U87MG-GFP建立恶性胶质母细胞瘤动物模型
培养工程化改造的U87MG-GFP细胞株,制备对数生长期的肿瘤细胞悬液;通过脑立体定位方式移植接种于BALB/c裸鼠右侧大脑CPU脑区,接种剂量5微升,肿瘤细胞数量为1×106个;连续观察裸鼠移植胶质瘤后症状,利用小动物磁共振成像仪监测胶质瘤的成瘤状态。磁共振成像(MRI)扫描过程中,使用MSME(multi spin multi echo)T1-weight序列获得功能像。胶质瘤细胞株接种后第4周核磁扫描结果如图9所示,未注射肿瘤细胞的健康裸鼠无肿瘤核磁信号(图9A),注射U87MG-GFP的裸鼠在CPU区域形成明显的肿瘤病灶(图9B),说明胶质母细胞瘤荷瘤动物建模成功。
实施例11:oHSVCH003-Δγ34.5-αPD1Ab-mCherry溶瘤病毒能高效溶杀恶性胶质母细胞瘤
将纯化制备的oHSVCH003-Δγ34.5-αPD1Ab-mCherry溶瘤病毒在建立的恶性胶质瘤荷瘤动物模型上进行了测试。将上述工程化构建的人脑星形胶质母细胞瘤(WHO IV级)细胞株U87MG-GFP定位接种于BALB/c裸鼠皮层下CPU脑区,4周后经核磁共振检测小鼠大脑已成瘤、呈侵袭性生长(图10A)。制备的oHSVCH003-Δγ34.5-αPD1Ab-mCherry溶瘤病毒通过瘤内给药方式注射到恶性胶质瘤瘤体内,14天后灌流裸鼠,取脑组织切片观察,发现oHSVCH003-Δγ34.5-αPD1Ab-mCherry溶瘤病毒在胶质母细胞瘤体内能有效复制增殖,在病毒感染的肿瘤组织区域出现明显的凋亡炎症反应(图10B),结果说明基于中国临床分离株HSV1-CH003构建的新型溶瘤病毒oHSVCH003-Δγ34.5-αPD1Ab-mCherry溶瘤病毒能高效溶杀恶性胶质母细胞瘤细胞,和注射PBS缓冲液的对照组荷瘤小鼠相比肿瘤组织体积明显缩小,验证了基于中国HSV临床分离株构建的增效溶瘤病毒具有良好的安全性和溶瘤活性。
显然,上述实施例仅仅是为清楚地说明所作的举例,而并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
SEQUENCE LISTING
<110> 深圳先进技术研究院
<120> 一种中国HSV临床分离株及基于其的溶瘤病毒和应用
<130> CP122010358C
<160> 15
<170> PatentIn version 3.3
<210> 1
<211> 440
<212> DNA
<213> 人工序列
<400> 1
cggggccgcg ggagcggggg gaggagcggg gggaggagcg gggggaggag cggggggagg 60
agcgggggga ggagcggggg gaggagcggg gggaggagcg gggggaggag cggggggagg 120
agcgggggga ggagcggggg gaggagcggg gggaggagcg gggggaggag cggggggagg 180
agcgggggga ggagcggggg gaggagcggg gggaggagcg gggggaggag cggggggagg 240
agcgggggga ggagcggcca gaccccaaaa acgggccccc cccgaaacac accccccggg 300
ggtcgcgcgc ggccctttaa agcgcggcgg cgcagcccgg gccccccgcg gctagcgagt 360
tagacaggca agcactactc gcctctgcac gcacatgctt gcctgtcaaa ctctaccacc 420
ccggcacgct ctctgtctcc 440
<210> 2
<211> 500
<212> DNA
<213> 人工序列
<400> 2
cgttacaccc gaggcggcct gggtcttccg cggagctccc gggagctccg caccaagccg 60
ctctccggag agacgatggc aggagccgcg catatatacg ctgggagccg gcccgccccc 120
aaggcgggcc cgccctcgga gggcgggact ggccaatcgg cggccgccag cgcggcgggg 180
cccggccaac cagcgtttgc cgagtcttcg gggcccggcc cactgggcgg taactcccgc 240
ccagtgggcc gggccgccca cttcccggta tggtaattaa aaacttgcaa gaggccttgt 300
tccgcttccc ggtatggtaa ttagaaactc attaatgggc ggccccggcc gcccttcccg 360
cttccggcaa ttcccgcggc ccttaatggg caaccccggt attccccgcc tcccgcgccg 420
cgcgtaacca ctcccctggg gttccgggtt atgctaattg cttttttggc ggaacacacg 480
gcccctcgcg cattggcccg 500
<210> 3
<211> 3538
<212> DNA
<213> 人工序列
<400> 3
gcgccgggtt ttggcgcctc ccgcgggcgc ccccctcctc acggcgagcg ctgccacgtc 60
agacgaaggg cgcaggagcg ttcctgatcc ttccgcccgg acgctcagga cagcggcccg 120
ctgctcataa gactcggcct tagaacccca gtatcagcag aaggacattt taggacggga 180
cttgggtgac tctagggcac tggttttctt tccagagagc ggaacaggcg aggaaaagta 240
gtcccttctc ggcgattctg cggagggatc tccgtggggc ggtgaacgcc gatgattata 300
taaggacgcg ccgggtgtgg cacagctagt tccgtcgcag ccgggatttg ggtcgcggtt 360
cttgtttgtg gatcgctgtg atcgtcactt ggtgagttgc gggctgctgg gctggccggg 420
gctttcgtgg ccgccgggcc gctcggtggg acggaagcgt gtggagagac cgccaagggc 480
tgtagtctgg gtccgcgagc aaggttgccc tgaactgggg gttgggggga gcgcacaaaa 540
tggcggctgt tcccgagtct tgaatggaag acgcttgtaa ggcgggctgt gaggtcgttg 600
aaacaaggtg gggggcatgg tgggcggcaa gaacccaagg tcttgaggcc ttcgctaatg 660
cgggaaagct cttattcggg tgagatgggc tggggcacca tctggggacc ctgacgtgaa 720
gtttgtcact gactggagaa ctcgggtttg tcgtctggtt gcgggggcgg cagttatgcg 780
gtgccgttgg gcagtgcacc cgtacctttg ggagcgcgcg cctcgtcgtg tcgtgacgtc 840
acccgttctg ttggcttata atgcagggtg gggccacctg ccggtaggtg tgcggtaggc 900
ttttctccgt cgcaggacgc agggttcggg cctagggtag gctctcctga atcgacaggc 960
gccggacctc tggtgagggg agggataagt gaggcgtcag tttctttggt cggttttatg 1020
tacctatctt cttaagtagc tgaagctccg gttttgaact atgcgctcgg ggttggcgag 1080
tgtgttttgt gaagtttttt aggcaccttt tgaaatgtaa tcatttgggt caatatgtaa 1140
ttttcagtgt tagactagta aagcttctgc aggtcgactc tagaaaattg tccgctaaat 1200
tctggccgtt tttggctttt ttgttagacg gcgcgccgtg gagaaccctg gacctatggt 1260
gagcaagggc gaggagctgt tcaccggggt ggtgcccatc ctggtcgagc tggacggcga 1320
cgtaaacggc cacaagttca gcgtgtccgg cgagggcgag ggcgatgcca cctacggcaa 1380
gctgaccctg aagttcatct gcaccaccgg caagctgccc gtgccctggc ccaccctcgt 1440
gaccaccctg acctacggcg tgcagtgctt cagccgctac cccgaccaca tgaagcagca 1500
cgacttcttc aagtccgcca tgcccgaagg ctacgtccag gagcgcacca tcttcttcaa 1560
ggacgacggc aactacaaga cccgcgccga ggtgaagttc gagggcgaca ccctggtgaa 1620
ccgcatcgag ctgaagggca tcgacttcaa ggaggacggc aacatcctgg ggcacaagat 1680
ggagtacaac tacaacagcc acaacgtcta tatcatggcc gacaagcaga agaacggcat 1740
caaggtgaac ttcaagatcc gccacaacat cgaggacggc agcgtgcagc tcgccgacca 1800
ctaccagcag aacaccccca tcggcgacgg ccccgtgctg ctgcccgaca accactacct 1860
gagcacccag tccgccctga gcaaagaccc caacgagaag cgcgatcaca tggtcctgct 1920
ggagttcgtg accgccgccg ggatcactct cggcatggac gagctgtaca agcagctgtt 1980
gaattttgac cttctcaagc tggcgggaga cgtcgagtcc aaccctgggc caatggtgag 2040
caagggcgag gagctgttca ccggggtggt gcccatcctg gtcgagctgg acggcgacgt 2100
aaacggccac aagttcagcg tgtccggcga gggcgagggc gatgccacct acggcaagct 2160
gaccctgaag ttcatctgca ccaccggcaa gctgcccgtg ccctggccca ccctcgtgac 2220
caccctgacc tacggcgtgc agtgcttcag ccgctacccc gaccacatga agcagcacga 2280
cttcttcaag tccgccatgc ccgaaggcta cgtccaggag cgcaccatct tcttcaagga 2340
cgacggcaac tacaagaccc gcgccgaggt gaagttcgag ggcgacaccc tggtgaaccg 2400
catcgagctg aagggcatcg acttcaagga ggacggcaac atcctggggc acaagatgga 2460
gtacaactac aacagccaca acgtctatat catggccgac aagcagaaga acggcatcaa 2520
ggtgaacttc aagatccgcc acaacatcga ggacggcagc gtgcagctcg ccgaccacta 2580
ccagcagaac acccccatcg gcgacggccc cgtgctgctg cccgacaacc actacctgag 2640
cacccagtcc gccctgagca aagaccccaa cgagaagcgc gatcacatgg tcctgctgga 2700
gttcgtgacc gccgccggga tcactctcgg catggacgag ctgtacaagg agggcagagg 2760
aagtctgcta acatgcggtg acgtcgagga gaatcctggc ccaatggtga gcaagggcga 2820
ggagctgttc accggggtgg tgcccatcct ggtcgagctg gacggcgacg taaacggcca 2880
caagttcagc gtgtccggcg agggcgaggg cgatgccacc tacggcaagc tgaccctgaa 2940
gttcatctgc accaccggca agctgcccgt gccctggccc accctcgtga ccaccctgac 3000
ctacggcgtg cagtgcttca gccgctaccc cgaccacatg aagcagcacg acttcttcaa 3060
gtccgccatg cccgaaggct acgtccagga gcgcaccatc ttcttcaagg acgacggcaa 3120
ctacaagacc cgcgccgagg tgaagttcga gggcgacacc ctggtgaacc gcatcgagct 3180
gaagggcatc gacttcaagg aggacggcaa catcctgggg cacaagatgg agtacaacta 3240
caacagccac aacgtctata tcatggccga caagcagaag aacggcatca aggtgaactt 3300
caagatccgc cacaacatcg aggacggcag cgtgcagctc gccgaccact accagcagaa 3360
cacccccatc ggcgacggcc ccgtgctgct gcccgacaac cactacctga gcacccagtc 3420
cgccctgagc aaagacccca acgagaagcg cgatcacatg gtcctgctgg agttcgtgac 3480
cgccgccggg atcactctcg gcatggacga gctgtacaag gaattcgata tcctatag 3538
<210> 4
<211> 846
<212> DNA
<213> 人工序列
<400> 4
aatcaacctc tggattacaa aatttgtgaa agattgactg gtattcttaa ctatgttgct 60
ccttttacgc tatgtggata cgctgcttta atgcctttgt atcatgctat tgcttcccgt 120
atggctttca ttttctcctc cttgtataaa tcctggttgc tgtctcttta tgaggagttg 180
tggcccgttg tcaggcaacg tggcgtggtg tgcactgtgt ttgctgacgc aacccccact 240
ggttggggca ttgccaccac ctgtcagctc ctttccggga ctttcgcttt ccccctccct 300
attgccacgg cggaactcat cgccgcctgc cttgcccgct gctggacagg ggctcggctg 360
ttgggcactg acaattccgt ggtgttgtcg gggaaatcat cgtcctttcc ttggctgctc 420
gcctgtgttg ccacctggat tctgcgcggg acgtccttct gctacgtccc ttcggccctc 480
aatccagcgg accttccttc ccgcggcctg ctgccggctc tgcggcctct tccgcgtctt 540
cgccttcgcc ctcagacgag tcggatctcc ctttgggccg cctccccgca gggcccgttt 600
aaacccgctg atcagcctcg actgtgcctt ctagttgcca gccatctgtt gtttgcccct 660
cccccgtgcc ttccttgacc ctggaaggtg ccactcccac tgtcctttcc taataaaatg 720
aggaaattgc atcgcattgt ctgagtaggt gtcattctat tctggggggt ggggtggggc 780
aggacagcaa gggggaggat tgggaagaca atagcaggca tgctggggat gcggtgggct 840
ctatgg 846
<210> 5
<211> 10031
<212> DNA
<213> 人工序列
<400> 5
gacggatcgg gagatctccc gatcccctat ggtgcactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgtcggggcc 240
gcgggagcgg ggggaggagc ggggggagga gcggggggag gagcgggggg aggagcgggg 300
ggaggagcgg ggggaggagc ggggggagga gcggggggag gagcgggggg aggagcgggg 360
ggaggagcgg ggggaggagc ggggggagga gcggggggag gagcgggggg aggagcgggg 420
ggaggagcgg ggggaggagc ggggggagga gcggggggag gagcgggggg aggagcgggg 480
ggaggagcgg ccagacccca aaaacgggcc ccccccgaaa cacacccccc gggggtcgcg 540
cgcggccctt taaagcgcgg cggcgcagcc cgggcccccc gcggctagcg agttagacag 600
gcaagcacta ctcgcctctg cacgcacatg cttgcctgtc aaactctacc accccggcac 660
gctctctgtc tccaccggtc catcgatgcg ccgggttttg gcgcctcccg cgggcgcccc 720
cctcctcacg gcgagcgctg ccacgtcaga cgaagggcgc aggagcgttc ctgatccttc 780
cgcccggacg ctcaggacag cggcccgctg ctcataagac tcggccttag aaccccagta 840
tcagcagaag gacattttag gacgggactt gggtgactct agggcactgg ttttctttcc 900
agagagcgga acaggcgagg aaaagtagtc ccttctcggc gattctgcgg agggatctcc 960
gtggggcggt gaacgccgat gattatataa ggacgcgccg ggtgtggcac agctagttcc 1020
gtcgcagccg ggatttgggt cgcggttctt gtttgtggat cgctgtgatc gtcacttggt 1080
gagttgcggg ctgctgggct ggccggggct ttcgtggccg ccgggccgct cggtgggacg 1140
gaagcgtgtg gagagaccgc caagggctgt agtctgggtc cgcgagcaag gttgccctga 1200
actgggggtt ggggggagcg cacaaaatgg cggctgttcc cgagtcttga atggaagacg 1260
cttgtaaggc gggctgtgag gtcgttgaaa caaggtgggg ggcatggtgg gcggcaagaa 1320
cccaaggtct tgaggccttc gctaatgcgg gaaagctctt attcgggtga gatgggctgg 1380
ggcaccatct ggggaccctg acgtgaagtt tgtcactgac tggagaactc gggtttgtcg 1440
tctggttgcg ggggcggcag ttatgcggtg ccgttgggca gtgcacccgt acctttggga 1500
gcgcgcgcct cgtcgtgtcg tgacgtcacc cgttctgttg gcttataatg cagggtgggg 1560
ccacctgccg gtaggtgtgc ggtaggcttt tctccgtcgc aggacgcagg gttcgggcct 1620
agggtaggct ctcctgaatc gacaggcgcc ggacctctgg tgaggggagg gataagtgag 1680
gcgtcagttt ctttggtcgg ttttatgtac ctatcttctt aagtagctga agctccggtt 1740
ttgaactatg cgctcggggt tggcgagtgt gttttgtgaa gttttttagg caccttttga 1800
aatgtaatca tttgggtcaa tatgtaattt tcagtgttag actagtaaag cttctgcagg 1860
tcgactctag aaaattgtcc gctaaattct ggccgttttt ggcttttttg ttagacggcg 1920
cgccgtggag aaccctggac ctatggtgag caagggcgag gagctgttca ccggggtggt 1980
gcccatcctg gtcgagctgg acggcgacgt aaacggccac aagttcagcg tgtccggcga 2040
gggcgagggc gatgccacct acggcaagct gaccctgaag ttcatctgca ccaccggcaa 2100
gctgcccgtg ccctggccca ccctcgtgac caccctgacc tacggcgtgc agtgcttcag 2160
ccgctacccc gaccacatga agcagcacga cttcttcaag tccgccatgc ccgaaggcta 2220
cgtccaggag cgcaccatct tcttcaagga cgacggcaac tacaagaccc gcgccgaggt 2280
gaagttcgag ggcgacaccc tggtgaaccg catcgagctg aagggcatcg acttcaagga 2340
ggacggcaac atcctggggc acaagatgga gtacaactac aacagccaca acgtctatat 2400
catggccgac aagcagaaga acggcatcaa ggtgaacttc aagatccgcc acaacatcga 2460
ggacggcagc gtgcagctcg ccgaccacta ccagcagaac acccccatcg gcgacggccc 2520
cgtgctgctg cccgacaacc actacctgag cacccagtcc gccctgagca aagaccccaa 2580
cgagaagcgc gatcacatgg tcctgctgga gttcgtgacc gccgccggga tcactctcgg 2640
catggacgag ctgtacaagc agctgttgaa ttttgacctt ctcaagctgg cgggagacgt 2700
cgagtccaac cctgggccaa tggtgagcaa gggcgaggag ctgttcaccg gggtggtgcc 2760
catcctggtc gagctggacg gcgacgtaaa cggccacaag ttcagcgtgt ccggcgaggg 2820
cgagggcgat gccacctacg gcaagctgac cctgaagttc atctgcacca ccggcaagct 2880
gcccgtgccc tggcccaccc tcgtgaccac cctgacctac ggcgtgcagt gcttcagccg 2940
ctaccccgac cacatgaagc agcacgactt cttcaagtcc gccatgcccg aaggctacgt 3000
ccaggagcgc accatcttct tcaaggacga cggcaactac aagacccgcg ccgaggtgaa 3060
gttcgagggc gacaccctgg tgaaccgcat cgagctgaag ggcatcgact tcaaggagga 3120
cggcaacatc ctggggcaca agatggagta caactacaac agccacaacg tctatatcat 3180
ggccgacaag cagaagaacg gcatcaaggt gaacttcaag atccgccaca acatcgagga 3240
cggcagcgtg cagctcgccg accactacca gcagaacacc cccatcggcg acggccccgt 3300
gctgctgccc gacaaccact acctgagcac ccagtccgcc ctgagcaaag accccaacga 3360
gaagcgcgat cacatggtcc tgctggagtt cgtgaccgcc gccgggatca ctctcggcat 3420
ggacgagctg tacaaggagg gcagaggaag tctgctaaca tgcggtgacg tcgaggagaa 3480
tcctggccca atggtgagca agggcgagga gctgttcacc ggggtggtgc ccatcctggt 3540
cgagctggac ggcgacgtaa acggccacaa gttcagcgtg tccggcgagg gcgagggcga 3600
tgccacctac ggcaagctga ccctgaagtt catctgcacc accggcaagc tgcccgtgcc 3660
ctggcccacc ctcgtgacca ccctgaccta cggcgtgcag tgcttcagcc gctaccccga 3720
ccacatgaag cagcacgact tcttcaagtc cgccatgccc gaaggctacg tccaggagcg 3780
caccatcttc ttcaaggacg acggcaacta caagacccgc gccgaggtga agttcgaggg 3840
cgacaccctg gtgaaccgca tcgagctgaa gggcatcgac ttcaaggagg acggcaacat 3900
cctggggcac aagatggagt acaactacaa cagccacaac gtctatatca tggccgacaa 3960
gcagaagaac ggcatcaagg tgaacttcaa gatccgccac aacatcgagg acggcagcgt 4020
gcagctcgcc gaccactacc agcagaacac ccccatcggc gacggccccg tgctgctgcc 4080
cgacaaccac tacctgagca cccagtccgc cctgagcaaa gaccccaacg agaagcgcga 4140
tcacatggtc ctgctggagt tcgtgaccgc cgccgggatc actctcggca tggacgagct 4200
gtacaaggaa ttcgatatcc tatagggtac caatcaacct ctggattaca aaatttgtga 4260
aagattgact ggtattctta actatgttgc tccttttacg ctatgtggat acgctgcttt 4320
aatgcctttg tatcatgcta ttgcttcccg tatggctttc attttctcct ccttgtataa 4380
atcctggttg ctgtctcttt atgaggagtt gtggcccgtt gtcaggcaac gtggcgtggt 4440
gtgcactgtg tttgctgacg caacccccac tggttggggc attgccacca cctgtcagct 4500
cctttccggg actttcgctt tccccctccc tattgccacg gcggaactca tcgccgcctg 4560
ccttgcccgc tgctggacag gggctcggct gttgggcact gacaattccg tggtgttgtc 4620
ggggaaatca tcgtcctttc cttggctgct cgcctgtgtt gccacctgga ttctgcgcgg 4680
gacgtccttc tgctacgtcc cttcggccct caatccagcg gaccttcctt cccgcggcct 4740
gctgccggct ctgcggcctc ttccgcgtct tcgccttcgc cctcagacga gtcggatctc 4800
cctttgggcc gcctccccgc agggcccgtt taaacccgct gatcagcctc gactgtgcct 4860
tctagttgcc agccatctgt tgtttgcccc tcccccgtgc cttccttgac cctggaaggt 4920
gccactccca ctgtcctttc ctaataaaat gaggaaattg catcgcattg tctgagtagg 4980
tgtcattcta ttctgggggg tggggtgggg caggacagca agggggagga ttgggaagac 5040
aatagcaggc atgctgggga tgcggtgggc tctatggtta attaacctgc aggcgttaca 5100
cccgaggcgg cctgggtctt ccgcggagct cccgggagct ccgcaccaag ccgctctccg 5160
gagagacgat ggcaggagcc gcgcatatat acgctgggag ccggcccgcc cccaaggcgg 5220
gcccgccctc ggagggcggg actggccaat cggcggccgc cagcgcggcg gggcccggcc 5280
aaccagcgtt tgccgagtct tcggggcccg gcccactggg cggtaactcc cgcccagtgg 5340
gccgggccgc ccacttcccg gtatggtaat taaaaacttg caagaggcct tgttccgctt 5400
cccggtatgg taattagaaa ctcattaatg ggcggccccg gccgcccttc ccgcttccgg 5460
caattcccgc ggcccttaat gggcaacccc ggtattcccc gcctcccgcg ccgcgcgtaa 5520
ccactcccct ggggttccgg gttatgctaa ttgctttttt ggcggaacac acggcccctc 5580
gcgcattggc ccgtctagag ggcccgttta aacccgctga tcagcctcga ctgtgccttc 5640
tagttgccag ccatctgttg tttgcccctc ccccgtgcct tccttgaccc tggaaggtgc 5700
cactcccact gtcctttcct aataaaatga ggaaattgca tcgcattgtc tgagtaggtg 5760
tcattctatt ctggggggtg gggtggggca ggacagcaag ggggaggatt gggaagacaa 5820
tagcaggcat gctggggatg cggtgggctc tatggcttct gaggcggaaa gaaccagctg 5880
gggctctagg gggtatcccc acgcgccctg tagcggcgca ttaagcgcgg cgggtgtggt 5940
ggttacgcgc agcgtgaccg ctacacttgc cagcgcccta gcgcccgctc ctttcgcttt 6000
cttcccttcc tttctcgcca cgttcgccgg ctttccccgt caagctctaa atcgggggct 6060
ccctttaggg ttccgattta gtgctttacg gcacctcgac cccaaaaaac ttgattaggg 6120
tgatggttca cgtagtgggc catcgccctg atagacggtt tttcgccctt tgacgttgga 6180
gtccacgttc tttaatagtg gactcttgtt ccaaactgga acaacactca accctatctc 6240
ggtctattct tttgatttat aagggatttt gccgatttcg gcctattggt taaaaaatga 6300
gctgatttaa caaaaattta acgcgaatta attctgtgga atgtgtgtca gttagggtgt 6360
ggaaagtccc caggctcccc agcaggcaga agtatgcaaa gcatgcatct caattagtca 6420
gcaaccaggt gtggaaagtc cccaggctcc ccagcaggca gaagtatgca aagcatgcat 6480
ctcaattagt cagcaaccat agtcccgccc ctaactccgc ccatcccgcc cctaactccg 6540
cccagttccg cccattctcc gccccatggc tgactaattt tttttattta tgcagaggcc 6600
gaggccgcct ctgcctctga gctattccag aagtagtgag gaggcttttt tggaggccta 6660
ggcttttgca aaaagctccc gggagcttgt atatccattt tcggatctga tcaagagaca 6720
ggatgaggat cgtttcgcat gattgaacaa gatggattgc acgcaggttc tccggccgct 6780
tgggtggaga ggctattcgg ctatgactgg gcacaacaga caatcggctg ctctgatgcc 6840
gccgtgttcc ggctgtcagc gcaggggcgc ccggttcttt ttgtcaagac cgacctgtcc 6900
ggtgccctga atgaactgca ggacgaggca gcgcggctat cgtggctggc cacgacgggc 6960
gttccttgcg cagctgtgct cgacgttgtc actgaagcgg gaagggactg gctgctattg 7020
ggcgaagtgc cggggcagga tctcctgtca tctcaccttg ctcctgccga gaaagtatcc 7080
atcatggctg atgcaatgcg gcggctgcat acgcttgatc cggctacctg cccattcgac 7140
caccaagcga aacatcgcat cgagcgagca cgtactcgga tggaagccgg tcttgtcgat 7200
caggatgatc tggacgaaga gcatcagggg ctcgcgccag ccgaactgtt cgccaggctc 7260
aaggcgcgca tgcccgacgg cgaggatctc gtcgtgaccc atggcgatgc ctgcttgccg 7320
aatatcatgg tggaaaatgg ccgcttttct ggattcatcg actgtggccg gctgggtgtg 7380
gcggaccgct atcaggacat agcgttggct acccgtgata ttgctgaaga gcttggcggc 7440
gaatgggctg accgcttcct cgtgctttac ggtatcgccg ctcccgattc gcagcgcatc 7500
gccttctatc gccttcttga cgagttcttc tgagcgggac tctggggttc gaaatgaccg 7560
accaagcgac gcccaacctg ccatcacgag atttcgattc caccgccgcc ttctatgaaa 7620
ggttgggctt cggaatcgtt ttccgggacg ccggctggat gatcctccag cgcggggatc 7680
tcatgctgga gttcttcgcc caccccaact tgtttattgc agcttataat ggttacaaat 7740
aaagcaatag catcacaaat ttcacaaata aagcattttt ttcactgcat tctagttgtg 7800
gtttgtccaa actcatcaat gtatcttatc atgtctgtat accgtcgacc tctagctaga 7860
gcttggcgta atcatggtca tagctgtttc ctgtgtgaaa ttgttatccg ctcacaattc 7920
cacacaacat acgagccgga agcataaagt gtaaagcctg gggtgcctaa tgagtgagct 7980
aactcacatt aattgcgttg cgctcactgc ccgctttcca gtcgggaaac ctgtcgtgcc 8040
agctgcatta atgaatcggc caacgcgcgg ggagaggcgg tttgcgtatt gggcgctctt 8100
ccgcttcctc gctcactgac tcgctgcgct cggtcgttcg gctgcggcga gcggtatcag 8160
ctcactcaaa ggcggtaata cggttatcca cagaatcagg ggataacgca ggaaagaaca 8220
tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa ggccgcgttg ctggcgtttt 8280
tccataggct ccgcccccct gacgagcatc acaaaaatcg acgctcaagt cagaggtggc 8340
gaaacccgac aggactataa agataccagg cgtttccccc tggaagctcc ctcgtgcgct 8400
ctcctgttcc gaccctgccg cttaccggat acctgtccgc ctttctccct tcgggaagcg 8460
tggcgctttc tcatagctca cgctgtaggt atctcagttc ggtgtaggtc gttcgctcca 8520
agctgggctg tgtgcacgaa ccccccgttc agcccgaccg ctgcgcctta tccggtaact 8580
atcgtcttga gtccaacccg gtaagacacg acttatcgcc actggcagca gccactggta 8640
acaggattag cagagcgagg tatgtaggcg gtgctacaga gttcttgaag tggtggccta 8700
actacggcta cactagaaga acagtatttg gtatctgcgc tctgctgaag ccagttacct 8760
tcggaaaaag agttggtagc tcttgatccg gcaaacaaac caccgctggt agcggttttt 8820
ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct 8880
tttctacggg gtctgacgct cagtggaacg aaaactcacg ttaagggatt ttggtcatga 8940
gattatcaaa aaggatcttc acctagatcc ttttaaatta aaaatgaagt tttaaatcaa 9000
tctaaagtat atatgagtaa acttggtctg acagttacca atgcttaatc agtgaggcac 9060
ctatctcagc gatctgtcta tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga 9120
taactacgat acgggagggc ttaccatctg gccccagtgc tgcaatgata ccgcgagacc 9180
cacgctcacc ggctccagat ttatcagcaa taaaccagcc agccggaagg gccgagcgca 9240
gaagtggtcc tgcaacttta tccgcctcca tccagtctat taattgttgc cgggaagcta 9300
gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt tgccattgct acaggcatcg 9360
tggtgtcacg ctcgtcgttt ggtatggctt cattcagctc cggttcccaa cgatcaaggc 9420
gagttacatg atcccccatg ttgtgcaaaa aagcggttag ctccttcggt cctccgatcg 9480
ttgtcagaag taagttggcc gcagtgttat cactcatggt tatggcagca ctgcataatt 9540
ctcttactgt catgccatcc gtaagatgct tttctgtgac tggtgagtac tcaaccaagt 9600
cattctgaga atagtgtatg cggcgaccga gttgctcttg cccggcgtca atacgggata 9660
ataccgcgcc acatagcaga actttaaaag tgctcatcat tggaaaacgt tcttcggggc 9720
gaaaactctc aaggatctta ccgctgttga gatccagttc gatgtaaccc actcgtgcac 9780
ccaactgatc ttcagcatct tttactttca ccagcgtttc tgggtgagca aaaacaggaa 9840
ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa atgttgaata ctcatactct 9900
tcctttttca atattattga agcatttatc agggttattg tctcatgagc ggatacatat 9960
ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg cacatttccc cgaaaagtgc 10020
cacctgacgt c 10031
<210> 6
<211> 819
<212> DNA
<213> 人工序列
<400> 6
atggacatcg tgcgcaccca gacccccagc agcctggccg tgagcgtggg cgagaaggtg 60
accatgagct gcaagagcag ccagagcctg ctgtacagca gcaaccagaa gaactacctg 120
gcctggtacc agcagaagcc cggccagagc cccaagctgc tgatctactg ggccagcacc 180
cgcgagagcg gcgtgcccga ccgcttcacc ggcagcggca gcggcaccga cttcaccctg 240
agcatcagca gcgtgaaggc cgaggacctg gccgtgtact actgccagca gtactacaac 300
tactggacct tcggcggcgg caccaagctg gagatcaagc gcgccgacgc cgcccccacc 360
gtgagcgaca tgcccatggc cgaccccaac cgcttccgcg gcaagaacct ggtgttccac 420
agcgagatca gcgaggtgaa gctggaggag agcggcggcg gcctggtgaa gctgggcggc 480
agcctgaagc tgagctgcgc cgccagcggc ttcaccttca gcacctacta catgagctgg 540
gtgcgccaga cccccgagcg ccgcctggag ctggtggccg ccatcaacag caacggcggc 600
agcacctact accccgacac cgtgcagggc cgcttcacca tcagccgcga caacgccaag 660
aacaccctgt acctgcagat gagcagcctg cgcagcgagg acaccgccct gtacctgtgc 720
gccagcctgg acggcaaggg ctaccacttc gactactggg gccagggcac ccccctgacc 780
gtgagcagcg ccaagaccac cccccccagc gtgtactag 819
<210> 7
<211> 711
<212> DNA
<213> 人工序列
<400> 7
atggtgagca agggcgagga ggataacatg gccatcatca aggagttcat gcgcttcaag 60
gtgcacatgg agggctccgt gaacggccac gagttcgaga tcgagggcga gggcgagggc 120
cgcccctacg agggcaccca gaccgccaag ctgaaggtga ccaagggtgg ccccctgccc 180
ttcgcctggg acatcctgtc ccctcagttc atgtacggct ccaaggccta cgtgaagcac 240
cccgccgaca tccccgacta cttgaagctg tccttccccg agggcttcaa gtgggagcgc 300
gtgatgaact tcgaggacgg cggcgtggtg accgtgaccc aggactcctc cctgcaggac 360
ggcgagttca tctacaaggt gaagctgcgc ggcaccaact tcccctccga cggccccgta 420
atgcagaaga agaccatggg ctgggaggcc tcctccgagc ggatgtaccc cgaggacggc 480
gccctgaagg gcgagatcaa gcagaggctg aagctgaagg acggcggcca ctacgacgct 540
gaggtcaaga ccacctacaa ggccaagaag cccgtgcagc tgcccggcgc ctacaacgtc 600
aacatcaagt tggacatcac ctcccacaac gaggactaca ccatcgtgga acagtacgaa 660
cgcgccgagg gccgccactc caccggcggc atggacgagc tgtacaagta g 711
<210> 8
<211> 1599
<212> DNA
<213> 人工序列
<400> 8
atggtgagca agggcgagga ggataacatg gccatcatca aggagttcat gcgcttcaag 60
gtgcacatgg agggctccgt gaacggccac gagttcgaga tcgagggcga gggcgagggc 120
cgcccctacg agggcaccca gaccgccaag ctgaaggtga ccaagggtgg ccccctgccc 180
ttcgcctggg acatcctgtc ccctcagttc atgtacggct ccaaggccta cgtgaagcac 240
cccgccgaca tccccgacta cttgaagctg tccttccccg agggcttcaa gtgggagcgc 300
gtgatgaact tcgaggacgg cggcgtggtg accgtgaccc aggactcctc cctgcaggac 360
ggcgagttca tctacaaggt gaagctgcgc ggcaccaact tcccctccga cggccccgta 420
atgcagaaga agaccatggg ctgggaggcc tcctccgagc ggatgtaccc cgaggacggc 480
gccctgaagg gcgagatcaa gcagaggctg aagctgaagg acggcggcca ctacgacgct 540
gaggtcaaga ccacctacaa ggccaagaag cccgtgcagc tgcccggcgc ctacaacgtc 600
aacatcaagt tggacatcac ctcccacaac gaggactaca ccatcgtgga acagtacgaa 660
cgcgccgagg gccgccactc caccggcggc atggacgagc tgtacaaggg aagcggagct 720
actaacttca gcctgctgaa gcaggctgga gacgtggagg agaaccctgg acctgctagc 780
atggacatcg tgcgcaccca gacccccagc agcctggccg tgagcgtggg cgagaaggtg 840
accatgagct gcaagagcag ccagagcctg ctgtacagca gcaaccagaa gaactacctg 900
gcctggtacc agcagaagcc cggccagagc cccaagctgc tgatctactg ggccagcacc 960
cgcgagagcg gcgtgcccga ccgcttcacc ggcagcggca gcggcaccga cttcaccctg 1020
agcatcagca gcgtgaaggc cgaggacctg gccgtgtact actgccagca gtactacaac 1080
tactggacct tcggcggcgg caccaagctg gagatcaagc gcgccgacgc cgcccccacc 1140
gtgagcgaca tgcccatggc cgaccccaac aggttcaggg gcaagaacct ggtgttccac 1200
agcgagatca gcgaggtgaa gctggaggag agcggcggcg gcctggtgaa gctgggcggc 1260
agcctgaagc tgagctgcgc cgccagcggc ttcaccttca gcacctacta catgagctgg 1320
gtgcgccaga cccccgagcg ccgcctggag ctggtggccg ccatcaacag caacggcggc 1380
agcacctact accccgacac cgtgcagggc cgcttcacca tcagccgcga caacgccaag 1440
aacaccctgt acctgcagat gagcagcctg cgcagcgagg acaccgccct gtacctgtgc 1500
gccagcctgg acggcaaggg ctaccacttc gactactggg gccagggcac ccccctgacc 1560
gtgagcagcg ccaagaccac cccccccagc gtgtactaa 1599
<210> 9
<211> 10795
<212> DNA
<213> 人工序列
<400> 9
gtcgacggat cgggagatct cccgatcccc tatggtgcac tctcagtaca atctgctctg 60
atgccgcata gttaagccag tatctgctcc ctgcttgtgt gttggaggtc gctgagtagt 120
gcgcgagcaa aatttaagct acaacaaggc aaggcttgac cgacaattgc atgaagaatc 180
tgcttagggt taggcgtttt gcgctgcttc gcgatgtacg ggccagatat acgcgttgac 240
attgattatt gactagttat taatagtaat caattacggg gtcattagtt catagcccat 300
atatggagtt ccgcgttaca taacttacgg taaatggccc gcctggctga ccgcccaacg 360
acccccgccc attgacgtca ataatgacgt atgttcccat agtaacgcca atagggactt 420
tccattgacg tcaatgggtg gagtatttac ggtaaactgc ccacttggca gtacatcaag 480
tgtatcatat gccaagtacg ccccctattg acgtcaatga cggtaaatgg cccgcctggc 540
attatgccca gtacatgacc ttatgggact ttcctacttg gcagtacatc tacgtattag 600
tcatcgctat taccatggtg atgcggtttt ggcagtacat caatgggcgt ggatagcggt 660
ttgactcacg gggatttcca agtctccacc ccattgacgt caatgggagt ttgttttggc 720
accaaaatca acgggacttt ccaaaatgtc gtaacaactc cgccccattg acgcaaatgg 780
gcggtaggcg tgtacggtgg gaggtctata taagcagcgc gttttgcctg tactgggtct 840
ctctggttag accagatctg agcctgggag ctctctggct aactagggaa cccactgctt 900
aagcctcaat aaagcttgcc ttgagtgctt caagtagtgt gtgcccgtct gttgtgtgac 960
tctggtaact agagatccct cagacccttt tagtcagtgt ggaaaatctc tagcagtggc 1020
gcccgaacag ggacttgaaa gcgaaaggga aaccagagga gctctctcga cgcaggactc 1080
ggcttgctga agcgcgcacg gcaagaggcg aggggcggcg actggtgagt acgccaaaaa 1140
ttttgactag cggaggctag aaggagagag atgggtgcga gagcgtcagt attaagcggg 1200
ggagaattag atcgcgatgg gaaaaaattc ggttaaggcc agggggaaag aaaaaatata 1260
aattaaaaca tatagtatgg gcaagcaggg agctagaacg attcgcagtt aatcctggcc 1320
tgttagaaac atcagaaggc tgtagacaaa tactgggaca gctacaacca tcccttcaga 1380
caggatcaga agaacttaga tcattatata atacagtagc aaccctctat tgtgtgcatc 1440
aaaggataga gataaaagac accaaggaag ctttagacaa gatagaggaa gagcaaaaca 1500
aaagtaagac caccgcacag caagcggccg ctgatcttca gacctggagg aggagatatg 1560
agggacaatt ggagaagtga attatataaa tataaagtag taaaaattga accattagga 1620
gtagcaccca ccaaggcaaa gagaagagtg gtgcagagag aaaaaagagc agtgggaata 1680
ggagctttgt tccttgggtt cttgggagca gcaggaagca ctatgggcgc agcgtcaatg 1740
acgctgacgg tacaggccag acaattattg tctggtatag tgcagcagca gaacaatttg 1800
ctgagggcta ttgaggcgca acagcatctg ttgcaactca cagtctgggg catcaagcag 1860
ctccaggcaa gaatcctggc tgtggaaaga tacctaaagg atcaacagct cctggggatt 1920
tggggttgct ctggaaaact catttgcacc actgctgtgc cttggaatgc tagttggagt 1980
aataaatctc tggaacagat ttggaatcac acgacctgga tggagtggga cagagaaatt 2040
aacaattaca caagcttaat acactcctta attgaagaat cgcaaaacca gcaagaaaag 2100
aatgaacaag aattattgga attagataaa tgggcaagtt tgtggaattg gtttaacata 2160
acaaattggc tgtggtatat aaaattattc ataatgatag taggaggctt ggtaggttta 2220
agaatagttt ttgctgtact ttctatagtg aatagagtta ggcagggata ttcaccatta 2280
tcgtttcaga cccacctccc aaccccgagg ggacccgaca ggcccgaagg aatagaagaa 2340
gaaggtggag agagagacag agacagatcc attcgattag tgaacggatc ggcactgcgt 2400
gcgccaattc tgcagacaaa tggcagtatt catccacaat tttaaaagaa aaggggggat 2460
tggggggtac agtgcagggg aaagaatagt agacataata gcaacagaca tacaaactaa 2520
agaattacaa aaacaaatta caaaaattca aaattttcgg gtttattaca gggacagcag 2580
agatccagtt tggttaatta agggtgcagc ggcctccgcg ccgggttttg gcgcctcccg 2640
cgggcgcccc cctcctcacg gcgagcgctg ccacgtcaga cgaagggcgc aggagcgttc 2700
ctgatccttc cgcccggacg ctcaggacag cggcccgctg ctcataagac tcggccttag 2760
aaccccagta tcagcagaag gacattttag gacgggactt gggtgactct agggcactgg 2820
ttttctttcc agagagcgga acaggcgagg aaaagtagtc ccttctcggc gattctgcgg 2880
agggatctcc gtggggcggt gaacgccgat gattatataa ggacgcgccg ggtgtggcac 2940
agctagttcc gtcgcagccg ggatttgggt cgcggttctt gtttgtggat cgctgtgatc 3000
gtcacttggt gagttgcggg ctgctgggct ggccggggct ttcgtggccg ccgggccgct 3060
cggtgggacg gaagcgtgtg gagagaccgc caagggctgt agtctgggtc cgcgagcaag 3120
gttgccctga actgggggtt ggggggagcg cacaaaatgg cggctgttcc cgagtcttga 3180
atggaagacg cttgtaaggc gggctgtgag gtcgttgaaa caaggtgggg ggcatggtgg 3240
gcggcaagaa cccaaggtct tgaggccttc gctaatgcgg gaaagctctt attcgggtga 3300
gatgggctgg ggcaccatct ggggaccctg acgtgaagtt tgtcactgac tggagaactc 3360
gggtttgtcg tctggttgcg ggggcggcag ttatgcggtg ccgttgggca gtgcacccgt 3420
acctttggga gcgcgcgcct cgtcgtgtcg tgacgtcacc cgttctgttg gcttataatg 3480
cagggtgggg ccacctgccg gtaggtgtgc ggtaggcttt tctccgtcgc aggacgcagg 3540
gttcgggcct agggtaggct ctcctgaatc gacaggcgcc ggacctctgg tgaggggagg 3600
gataagtgag gcgtcagttt ctttggtcgg ttttatgtac ctatcttctt aagtagctga 3660
agctccggtt ttgaactatg cgctcggggt tggcgagtgt gttttgtgaa gttttttagg 3720
caccttttga aatgtaatca tttgggtcaa tatgtaattt tcagtgttag actagtaaat 3780
tgtccgctaa attctggccg tttttggctt ttttgttaga cgaagcttgg gctgcaggtc 3840
gactatagag gatccatggt gagcaagggc gaggaggata acatggccat catcaaggag 3900
ttcatgcgct tcaaggtgca catggagggc tccgtgaacg gccacgagtt cgagatcgag 3960
ggcgagggcg agggccgccc ctacgagggc acccagaccg ccaagctgaa ggtgaccaag 4020
ggtggccccc tgcccttcgc ctgggacatc ctgtcccctc agttcatgta cggctccaag 4080
gcctacgtga agcaccccgc cgacatcccc gactacttga agctgtcctt ccccgagggc 4140
ttcaagtggg agcgcgtgat gaacttcgag gacggcggcg tggtgaccgt gacccaggac 4200
tcctccctgc aggacggcga gttcatctac aaggtgaagc tgcgcggcac caacttcccc 4260
tccgacggcc ccgtaatgca gaagaagacc atgggctggg aggcctcctc cgagcggatg 4320
taccccgagg acggcgccct gaagggcgag atcaagcaga ggctgaagct gaaggacggc 4380
ggccactacg acgctgaggt caagaccacc tacaaggcca agaagcccgt gcagctgccc 4440
ggcgcctaca acgtcaacat caagttggac atcacctccc acaacgagga ctacaccatc 4500
gtggaacagt acgaacgcgc cgagggccgc cactccaccg gcggcatgga cgagctgtac 4560
aagggaagcg gagctactaa cttcagcctg ctgaagcagg ctggagacgt ggaggagaac 4620
cctggacctg ctagcatgga catcgtgcgc acccagaccc ccagcagcct ggccgtgagc 4680
gtgggcgaga aggtgaccat gagctgcaag agcagccaga gcctgctgta cagcagcaac 4740
cagaagaact acctggcctg gtaccagcag aagcccggcc agagccccaa gctgctgatc 4800
tactgggcca gcacccgcga gagcggcgtg cccgaccgct tcaccggcag cggcagcggc 4860
accgacttca ccctgagcat cagcagcgtg aaggccgagg acctggccgt gtactactgc 4920
cagcagtact acaactactg gaccttcggc ggcggcacca agctggagat caagcgcgcc 4980
gacgccgccc ccaccgtgag cgacatgccc atggccgacc ccaacaggtt caggggcaag 5040
aacctggtgt tccacagcga gatcagcgag gtgaagctgg aggagagcgg cggcggcctg 5100
gtgaagctgg gcggcagcct gaagctgagc tgcgccgcca gcggcttcac cttcagcacc 5160
tactacatga gctgggtgcg ccagaccccc gagcgccgcc tggagctggt ggccgccatc 5220
aacagcaacg gcggcagcac ctactacccc gacaccgtgc agggccgctt caccatcagc 5280
cgcgacaacg ccaagaacac cctgtacctg cagatgagca gcctgcgcag cgaggacacc 5340
gccctgtacc tgtgcgccag cctggacggc aagggctacc acttcgacta ctggggccag 5400
ggcacccccc tgaccgtgag cagcgccaag accacccccc ccagcgtgta ctaaggcgcg 5460
ccgaattcga tatcaagctt atcgataatc aacctctgga ttacaaaatt tgtgaaagat 5520
tgactggtat tcttaactat gttgctcctt ttacgctatg tggatacgct gctttaatgc 5580
ctttgtatca tgctattgct tcccgtatgg ctttcatttt ctcctccttg tataaatcct 5640
ggttgctgtc tctttatgag gagttgtggc ccgttgtcag gcaacgtggc gtggtgtgca 5700
ctgtgtttgc tgacgcaacc cccactggtt ggggcattgc caccacctgt cagctccttt 5760
ccgggacttt cgctttcccc ctccctattg ccacggcgga actcatcgcc gcctgccttg 5820
cccgctgctg gacaggggct cggctgttgg gcactgacaa ttccgtggtg ttgtcgggga 5880
aatcatcgtc ctttccttgg ctgctcgcct gtgttgccac ctggattctg cgcgggacgt 5940
ccttctgcta cgtcccttcg gccctcaatc cagcggacct tccttcccgc ggcctgctgc 6000
cggctctgcg gcctcttccg cgtcttcgcc ttcgccctca gacgagtcgg atctcccttt 6060
gggccgcctc cccgcatcga taccgtcgac ctcgagacct agaaaaacat ggagcaatca 6120
caagtagcaa tacagcagct accaatgctg attgtgcctg gctagaagca caagaggagg 6180
aggaggtggg ttttccagtc acacctcagg tacctttaag accaatgact tacaaggcag 6240
ctgtagatct tagccacttt ttaaaagaaa aggggggact ggaagggcta attcactccc 6300
aacgaagaca agatatcctt gatctgtgga tctaccacac acaaggctac ttccctgatt 6360
ggcagaacta cacaccaggg ccagggatca gatatccact gacctttgga tggtgctaca 6420
agctagtacc agttgagcaa gagaaggtag aagaagccaa tgaaggagag aacacccgct 6480
tgttacaccc tgtgagcctg catgggatgg atgacccgga gagagaagta ttagagtgga 6540
ggtttgacag ccgcctagca tttcatcaca tggcccgaga gctgcatccg gactgtactg 6600
ggtctctctg gttagaccag atctgagcct gggagctctc tggctaacta gggaacccac 6660
tgcttaagcc tcaataaagc ttgccttgag tgcttcaagt agtgtgtgcc cgtctgttgt 6720
gtgactctgg taactagaga tccctcagac ccttttagtc agtgtggaaa atctctagca 6780
gggcccgttt aaacccgctg atcagcctcg actgtgcctt ctagttgcca gccatctgtt 6840
gtttgcccct cccccgtgcc ttccttgacc ctggaaggtg ccactcccac tgtcctttcc 6900
taataaaatg aggaaattgc atcgcattgt ctgagtaggt gtcattctat tctggggggt 6960
ggggtggggc aggacagcaa gggggaggat tgggaagaca atagcaggca tgctggggat 7020
gcggtgggct ctatggcttc tgaggcggaa agaaccagct ggggctctag ggggtatccc 7080
cacgcgccct gtagcggcgc attaagcgcg gcgggtgtgg tggttacgcg cagcgtgacc 7140
gctacacttg ccagcgccct agcgcccgct cctttcgctt tcttcccttc ctttctcgcc 7200
acgttcgccg gctttccccg tcaagctcta aatcgggggc tccctttagg gttccgattt 7260
agtgctttac ggcacctcga ccccaaaaaa cttgattagg gtgatggttc acgtagtggg 7320
ccatcgccct gatagacggt ttttcgccct ttgacgttgg agtccacgtt ctttaatagt 7380
ggactcttgt tccaaactgg aacaacactc aaccctatct cggtctattc ttttgattta 7440
taagggattt tgccgatttc ggcctattgg ttaaaaaatg agctgattta acaaaaattt 7500
aacgcgaatt aattctgtgg aatgtgtgtc agttagggtg tggaaagtcc ccaggctccc 7560
cagcaggcag aagtatgcaa agcatgcatc tcaattagtc agcaaccagg tgtggaaagt 7620
ccccaggctc cccagcaggc agaagtatgc aaagcatgca tctcaattag tcagcaacca 7680
tagtcccgcc cctaactccg cccatcccgc ccctaactcc gcccagttcc gcccattctc 7740
cgccccatgg ctgactaatt ttttttattt atgcagaggc cgaggccgcc tctgcctctg 7800
agctattcca gaagtagtga ggaggctttt ttggaggcct aggcttttgc aaaaagctcc 7860
cgggagcttg tatatccatt ttcggatctg atcagcacgt gttgacaatt aatcatcggc 7920
atagtatatc ggcatagtat aatacgacaa ggtgaggaac taaaccatgg ccaagttgac 7980
cagtgccgtt ccggtgctca ccgcgcgcga cgtcgccgga gcggtcgagt tctggaccga 8040
ccggctcggg ttctcccggg acttcgtgga ggacgacttc gccggtgtgg tccgggacga 8100
cgtgaccctg ttcatcagcg cggtccagga ccaggtggtg ccggacaaca ccctggcctg 8160
ggtgtgggtg cgcggcctgg acgagctgta cgccgagtgg tcggaggtcg tgtccacgaa 8220
cttccgggac gcctccgggc cggccatgac cgagatcggc gagcagccgt gggggcggga 8280
gttcgccctg cgcgacccgg ccggcaactg cgtgcacttc gtggccgagg agcaggactg 8340
acacgtgcta cgagatttcg attccaccgc cgccttctat gaaaggttgg gcttcggaat 8400
cgttttccgg gacgccggct ggatgatcct ccagcgcggg gatctcatgc tggagttctt 8460
cgcccacccc aacttgttta ttgcagctta taatggttac aaataaagca atagcatcac 8520
aaatttcaca aataaagcat ttttttcact gcattctagt tgtggtttgt ccaaactcat 8580
caatgtatct tatcatgtct gtataccgtc gacctctagc tagagcttgg cgtaatcatg 8640
gtcatagctg tttcctgtgt gaaattgtta tccgctcaca attccacaca acatacgagc 8700
cggaagcata aagtgtaaag cctggggtgc ctaatgagtg agctaactca cattaattgc 8760
gttgcgctca ctgcccgctt tccagtcggg aaacctgtcg tgccagctgc attaatgaat 8820
cggccaacgc gcggggagag gcggtttgcg tattgggcgc tcttccgctt cctcgctcac 8880
tgactcgctg cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt 8940
aatacggtta tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca 9000
gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc 9060
ccctgacgag catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact 9120
ataaagatac caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgaccct 9180
gccgcttacc ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcatag 9240
ctcacgctgt aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca 9300
cgaacccccc gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa 9360
cccggtaaga cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc 9420
gaggtatgta ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag 9480
aagaacagta tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg 9540
tagctcttga tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca 9600
gcagattacg cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc 9660
tgacgctcag tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag 9720
gatcttcacc tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata 9780
tgagtaaact tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat 9840
ctgtctattt cgttcatcca tagttgcctg actccccgtc gtgtagataa ctacgatacg 9900
ggagggctta ccatctggcc ccagtgctgc aatgataccg cgagacccac gctcaccggc 9960
tccagattta tcagcaataa accagccagc cggaagggcc gagcgcagaa gtggtcctgc 10020
aactttatcc gcctccatcc agtctattaa ttgttgccgg gaagctagag taagtagttc 10080
gccagttaat agtttgcgca acgttgttgc cattgctaca ggcatcgtgg tgtcacgctc 10140
gtcgtttggt atggcttcat tcagctccgg ttcccaacga tcaaggcgag ttacatgatc 10200
ccccatgttg tgcaaaaaag cggttagctc cttcggtcct ccgatcgttg tcagaagtaa 10260
gttggccgca gtgttatcac tcatggttat ggcagcactg cataattctc ttactgtcat 10320
gccatccgta agatgctttt ctgtgactgg tgagtactca accaagtcat tctgagaata 10380
gtgtatgcgg cgaccgagtt gctcttgccc ggcgtcaata cgggataata ccgcgccaca 10440
tagcagaact ttaaaagtgc tcatcattgg aaaacgttct tcggggcgaa aactctcaag 10500
gatcttaccg ctgttgagat ccagttcgat gtaacccact cgtgcaccca actgatcttc 10560
agcatctttt actttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc 10620
aaaaaaggga ataagggcga cacggaaatg ttgaatactc atactcttcc tttttcaata 10680
ttattgaagc atttatcagg gttattgtct catgagcgga tacatatttg aatgtattta 10740
gaaaaataaa caaatagggg ttccgcgcac atttccccga aaagtgccac ctgac 10795
<210> 10
<211> 27
<212> DNA
<213> 人工序列
<400> 10
gcgccgggtt ttggcgcctc ccgcggg 27
<210> 11
<211> 28
<212> DNA
<213> 人工序列
<400> 11
ctataggata tcgaattcct tgtacagc 28
<210> 12
<211> 48
<212> DNA
<213> 人工序列
<400> 12
gtacgggcca gatatacgcg tcggggccgc gggagcgggg ggaggagc 48
<210> 13
<211> 49
<212> DNA
<213> 人工序列
<400> 13
ttaacccatc gatggaccgg tggagacaga gagcgtgccg gggtggtag 49
<210> 14
<211> 51
<212> DNA
<213> 人工序列
<400> 14
aatccttaat taaggcctgc aggcgttaca cccgaggcgg cctgggtctt c 51
<210> 15
<211> 47
<212> DNA
<213> 人工序列
<400> 15
ggtttaaacg ggccctctag acgggccaat gcgcgagggg ccgtgtg 47
Claims (10)
1.一种单纯疱疹病毒HSV1-CH003株,其特征在于,其保藏编号为CCTCC NO:V202210。
2.一种病毒载体,其特征在于,通过敲除单纯疱疹病毒HSV1-CH003株基因组中神经毒力因子γ34.5双拷贝基因得到。
3.根据权利要求2所述的病毒载体,其特征在于,所述病毒载体在敲除的γ34.5基因座位插入外源基因表达盒;或,
所述病毒载体还包括在其基因组任何插入不影响功能的位点插入外源基因表达盒;
所述外源基因表达盒中的外源基因选自表达任意目的蛋白的基因。
4.权利要求2或3所述的病毒载体在病毒学基础研究、作为大携载容量病毒载体、作为溶瘤病毒、作为目的基因递送载体、作为神经系统靶向基因治疗药物、在动物感染模型建立或抗病毒药物筛选中的应用。
5.一种重组溶瘤病毒,其特征在于,通过敲除单纯疱疹病毒HSV1-CH003株基因组中神经毒力因子γ34.5双拷贝基因得到。
6.根据权利要求5所述的重组溶瘤病毒,其特征在于,溶瘤病毒载体还包括在敲除的γ34.5基因座位插入肿瘤治疗序列基因表达盒;或,
所述溶瘤病毒载体基因组还包括在任何插入不影响功能的位点插入肿瘤治疗序列基因表达盒;
优选地,所述肿瘤治疗序列基因选自免疫检查点蛋白抗体基因、肿瘤免疫治疗细胞因子基因和免疫调控增强基因中的一种或以上;
优选地,所述肿瘤治疗序列基因表达盒包含启动子和肿瘤治疗序列基因;
优选地,在肿瘤治疗序列基因下游引入WPRE增强表达元件;
优选地,所述肿瘤治疗序列基因为免疫检查点蛋白PD1抗体基因;
优选地,在敲除的γ34.5基因座位还插入荧光蛋白表达盒,所述荧光蛋白表达盒的转录方向与所述肿瘤治疗序列基因表达盒保持一致。
7.权利要求5或6所述的重组溶瘤病毒在制备治疗抗肿瘤药物中的用途;
优选地,所述肿瘤包括脑瘤、恶性胶质母细胞瘤、宫颈癌、肺癌、胃肠癌、头颈癌、恶性间皮瘤、乳腺癌、恶性黑素瘤、血液肿瘤、多发性骨髓瘤、急性髓性白血病、慢性髓性白血病、非小细胞肺癌、结直肠癌、前列腺癌、卵巢癌、肝癌、肾癌、胰腺癌、胃癌、食道癌、胆管癌、头颈部鳞状细胞癌、软组织肉瘤和小细胞肺癌。
8.一种抗肿瘤药物组合物,其特征在于,包含权利要求5或6所述的重组溶瘤病毒。
9.一种重组溶瘤病毒的构建方法,其特征在于,敲除单纯疱疹病毒HSV1-CH003株基因组中神经毒力因子γ34.5双拷贝基因;
优选地,还包括在敲除的γ34.5基因座位或基因组任何插入不影响功能的位点插入肿瘤治疗序列基因表达盒。
10.一种重组溶瘤病毒的构建方法,其特征在于,包括如下步骤:
(1)靶向载体构建
克隆γ34.5基因上下游同源臂,将克隆的上下游同源臂片段连入骨架载体,获得重组载体1;构建包括启动子、绿色荧光蛋白基因和WPRE片段的EGFP表达盒,连入重组载体1,获得表达绿色荧光蛋白的重组靶向质粒载体;
优选地,还包括在重组载体1插入肿瘤治疗序列基因表达盒,具体地:构建包括启动子、肿瘤治疗序列基因和红色荧光蛋白mCherry基因通过自剪切肽(2A)绑定表达的肿瘤治疗序列基因表达盒,替换表达绿色荧光蛋白的重组靶向质粒载体的EGFP表达盒,获得表达肿瘤治疗序列基因的重组靶向质粒载体;
(2)重组溶瘤病毒构建
将敲除γ34.5基因表达绿色荧光蛋白的重组靶向质粒载体与HSV1-CH003临床株病毒基因组DNA共转染293T细胞,待细胞病变后收集上清,感染Vero细胞,挑斑绿色荧光的病毒嗜斑,经过5轮以上的挑斑纯化后即得表达绿色荧光蛋白的HSV1-CH003重组病毒;
优选地,插入肿瘤治疗序列基因的重组溶瘤病毒的构建,方法包括:将表达肿瘤治疗序列基因的重组靶向质粒载体与表达绿色荧光蛋白的重组HSV1-CH003株病毒基因组DNA共转染293T细胞,待细胞病变后收集上清,感染Vero细胞,在绿色荧光背景下挑斑红色荧光的病毒斑,经过5轮以上的挑斑纯化后即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210660127.0A CN117264908A (zh) | 2022-06-13 | 2022-06-13 | 一种中国hsv临床分离株及基于其的溶瘤病毒和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210660127.0A CN117264908A (zh) | 2022-06-13 | 2022-06-13 | 一种中国hsv临床分离株及基于其的溶瘤病毒和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117264908A true CN117264908A (zh) | 2023-12-22 |
Family
ID=89212946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210660127.0A Pending CN117264908A (zh) | 2022-06-13 | 2022-06-13 | 一种中国hsv临床分离株及基于其的溶瘤病毒和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117264908A (zh) |
-
2022
- 2022-06-13 CN CN202210660127.0A patent/CN117264908A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019203955C1 (en) | Multipartite signaling proteins and uses thereof | |
CN110656090B (zh) | 一种表达质粒、用于包装容量增加的二代腺病毒的细胞株及其应用 | |
CN111479921A (zh) | 用于以基因方式修饰且扩增淋巴细胞以及调节其活性的方法及组合物 | |
CN110835633B (zh) | 利用优化的基因密码子扩展系统制备ptc稳定细胞系及应用 | |
AU2016343979A1 (en) | Delivery of central nervous system targeting polynucleotides | |
CN113166780A (zh) | 用于治疗gm1和gm2神经节苷脂贮积病的raav载体 | |
KR20220149588A (ko) | 대사성 간 장애의 치료를 위한 조성물 및 방법 | |
KR102584628B1 (ko) | T-세포 수용체, t-세포 항원 및 이들의 기능성 상호작용의 식별 및 특징규명을 위한 조작된 다성분 시스템 | |
CN113186167B (zh) | 用于测定抗cd20单克隆抗体药物adcp生物学活性的方法 | |
JP2003534775A (ja) | タンパク質を不安定化する方法とその使用 | |
KR101201020B1 (ko) | 감마-카르복실화된 단백질의 제조 방법 | |
KR20220002910A (ko) | 효율적인 rna 트랜스-스플라이싱을 위한 삼중 나선 종결인자 | |
KR20230019063A (ko) | C9orf72 연관 질환의 치료를 위한 삼중 기능 아데노-연관 바이러스 (aav) 벡터 | |
JP2023025182A (ja) | T細胞レセプター及びt細胞抗原の同定及び特徴決定のための遺伝子操作された多成分システム | |
CN110214182A (zh) | 用于i型黏多糖贮积症的基因治疗 | |
AU2019219286A1 (en) | Oligodendrocyte-specific promoter, miRNA specific to PLP1 gene, vector including said promoter and/or miRNA, and pharmaceutical composition including said vector | |
KR20210118402A (ko) | 위스콧-알드리치(Wiskott-Aldrich) 증후군에 대한 조혈 줄기 세포-유전자 치료요법 | |
CN114606251A (zh) | 以外泌体为载体的dna递送系统 | |
CN101180082A (zh) | 利用siv-pedf载体治疗伴随眼组织细胞凋亡变性的疾患的药物 | |
CN113637724B (zh) | SARS-CoV-2冠状病毒3C蛋白酶活性抑制剂的筛选方法及筛选试剂盒 | |
CN101160139A (zh) | 含有pedf以及fgf2的伴随眼组织细胞凋亡变性的疾患的治疗药物 | |
CN117264908A (zh) | 一种中国hsv临床分离株及基于其的溶瘤病毒和应用 | |
CN116135972A (zh) | 基于中国hsv临床分离株的溶瘤病毒及其构建方法和应用 | |
WO2022241455A1 (en) | A synthetic circuit for buffering gene dosage variation between individual mammalian cells | |
CN110777147A (zh) | 一种ikzf3基因沉默的t细胞及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |